Destiny Pharma Plc
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection (NCT03915470) | Destiny Pharma Plc | 2019-08-29 |
Track Destiny Pharma Plc automatically
Every clearance here is in the API, with alerts when new ones post.